Novo Nordisk reported Phase 3 data showing its combination candidate CagriSema improved glycemic control and drove larger mean weight loss than semaglutide in people with type 2 diabetes. The company said CagriSema met its primary endpoints and demonstrated clinically meaningful weight and HbA1c reductions across a large randomized population. Novo released secondary analyses indicating potential superiority on several metabolic endpoints versus semaglutide; company statements emphasized the therapy’s role in tightening the competitive landscape for next‑generation metabolic drugs. The trial results add fuel to the intensifying rivalry among Novo, Lilly and new entrants racing to define next‑gen metabolic standards. Why it matters: Positive Phase 3 evidence for a combination amylin‑GLP‑1 approach could shift prescribing patterns and payer negotiations, and it raises the bar for competitors developing single‑agent or monthly regimens.